Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HeraMED Ltd. ( (AU:HMD) ) just unveiled an announcement.
HeraMED Limited has issued 41,300,685 fully paid ordinary shares on 4 February 2026, in line with a prior capital-related announcement and a corresponding Appendix 2A filing. The company confirmed the new shares were issued without a prospectus under the relevant Corporations Act provisions and stated it remains compliant with its continuous disclosure and financial reporting obligations, with no excluded information outstanding, providing regulatory clarity and transparency for existing and new shareholders regarding the expanded capital base.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
More about HeraMED Ltd.
HeraMED Limited (ASX:HMD) is an innovative medical data and technology company focused on digitally transforming maternity care through a hybrid maternity care platform. Its proprietary solutions, including the HeraCARE maternal health ecosystem and the clinically validated in-home fetal and maternal heart rate monitor HeraBEAT, combine hardware, software, cloud computing, artificial intelligence and big data to enhance prenatal and postpartum care, improve engagement of expectant mothers, support healthcare professionals, and enable early detection and prevention of risks at lower cost.
YTD Price Performance: 22.22%
Average Trading Volume: 898,607
Technical Sentiment Signal: Buy
Current Market Cap: A$46.02M
For an in-depth examination of HMD stock, go to TipRanks’ Overview page.